Home » Fitness, Health & Medicine, Manufacturing & Industry, Marketing & Sales, Pharmaceuticals & Biotech » CIS Insulin Market is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%: Hexa Reports
The “CIS Market” for insulin and insulin products is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver.

The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

Browse Detailed Report with TOC at:

Further key findings from the study suggest:

Regionally, Russia occupied the largest share of the market, accounting for 69.2% of the revenue. Its large share is majorly attributed by the subsidies that Russian government provides to make insulin more affordable for patients.

Ukraine is expected to register the fastest CAGR of 15.6% during the forecast period due to the presence of high untapped opportunities and encouraging government initiatives.
In addition, Poland is expected to grow at a lucrative rate during the forecast period majorly owing to the presence of high diabetes prevalence coupled with increasing healthcare expenditures.

Long acting insulin accounted for the largest share of the market, at over 39.0% in 2013, owing to the higher preference given to long acting insulin therapy for diabetes which results in lesser episodes of low blood sugar. It is also expected that this product segment will grow at the fastest CAGR of over 18.0% during the next six years.

Application of insulin for control of type II diabetes occupied for over 90.0% of the market owing to the presence of larger portfolio of products catering to this segment and a relatively larger prevalence base.

Analogs accounted for over 80.0% of the revenue owing to their relatively higher prices and better efficacy levels. In addition, this segment is expected to exhibit the fastest CAGR during the forecast period on account of the introduction of technologically advanced products such as ultra-long and ultra-fast acting analogs.

Browse Pharmaceutical Related Report :

Top ICT spenders in the Australian Pharmaceutical Industry:

Global Cholesterol Industry 2015:

Global Cervical Cancer Market 2015-2019:

For the purpose of this study, Grand View Research has segmented the CIS Insulin market on the basis of product, application, source and region:

CIS Insulin Product Outlook
Rapid Acting
Long Acting
Premixed Analog
Short Acting
Intermediate Acting
CIS Insulin Application Outlook
Type II Diabetes
Type I Diabetes
CIS Insulin Source Outlook
Human Recombinant
CIS Insulin Regional Outlook
Rest of CIS

Request a Sample of “CIS Insulin Market” Report at:

About Us:

Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe.We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Media Contact
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Email: sales@hexareports.com
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://www.hexareports.com/report/cis-insulin-market-rapid-acting-short-acting-pre-mixed-long-acting-type-i-amp-ii-diabetes-analogs-recombinant-insulin-analysis-and-segment-forecasts-to-2020/details

Comments are closed.